Intermittent versus continuous esketamine infusions for long-term pain modulation in complex regional pain syndrome: protocol of a randomized controlled non-inferiority study (KetCRPS-2)

Thomas J P Mangnus, Maaike Dirckx, Krishna D Bharwani, Sara J Baart, Theodora A M Siepman, Ken Redekop, Willem A Dik, Cecile C de Vos, Frank J P M Huygen, Thomas J P Mangnus, Maaike Dirckx, Krishna D Bharwani, Sara J Baart, Theodora A M Siepman, Ken Redekop, Willem A Dik, Cecile C de Vos, Frank J P M Huygen

Abstract

Background: Complex regional pain syndrome (CRPS) is a chronic pain condition of an extremity. While achieving pain relief in CRPS is challenging, esketamine infusions can accomplish pain relief for several weeks post-infusion in a subgroup of CRPS patients. Unfortunately, CRPS esketamine protocols are very heterogeneous in advice on dosage, administration and treatment setting. Currently, no trials are available that study differences between intermittent and continuous esketamine infusions for CRPS. With the current situation of bed shortages, it is difficult to admit patients for several consecutive days for inpatient esketamine treatments. In this study, we investigate whether 6 intermittent outpatient esketamine treatments are not inferior to a continuous 6-day inpatient esketamine treatment in establishing pain relief. In addition, several secondary study parameters will be assessed in order to investigate mechanisms responsible for pain relief by esketamine infusions. Furthermore, the cost-effectiveness will be analyzed.

Methods: In this RCT, the primary objective is to demonstrate that an intermittent esketamine dosing regimen is non-inferior to a continuous esketamine dosing regimen at 3 months follow-up. We will include 60 adult CRPS patients. The inpatient treatment group receives a continuous intravenous esketamine infusion for 6 consecutive days. The outpatient treatment group receives a 6-hour intravenous esketamine infusion every 2 weeks for 3 months. Esketamine dose will be individually tailored and is started at 0.05 mg/kg/h and can be increased to a maximum of 0.2 mg/kg/h. Each patient will be followed for 6 months. The primary study parameter is perceived pain intensity, measured by an 11-point Numerical Rating Scale. Secondary study parameters are conditioned pain modulation, quantitative sensory testing, adverse events, thermography, blood inflammatory parameter, questionnaires about functionality, quality of life and mood and costs per patient.

Discussion: If our study reveals non-inferiority between intermittent and continuous esketamine infusions, these findings can be beneficial to increase the availability and flexibility of esketamine infusions through outpatient treatments. Furthermore, the costs of outpatient esketamine infusions could be lower than inpatient esketamine infusions. In addition, secondary parameters may predict response to esketamine treatment.

Trial registration: ClinicalTrials.gov Identifier NCT05212571 , date of registration 01-28-2022.

Protocol version: Version 3, February 2022.

Keywords: CRPS; Complex regional pain syndrome; Esketamine; Inpatient; KetCRPS-2; Ketamine; Outpatient; Study protocol.

Conflict of interest statement

The authors report no conflicts of interest that are relevant or related to the content of this article.

© 2023. The Author(s).

Figures

Fig. 1
Fig. 1
Detailed flowchart of the KetCRPS-2 study Abbreviations: Complex Regional Pain Syndrome (CRPS), Numerical Rating Scale (NRS), Global Perceived Effect(GPE), the Core Outcome Measurement set for complex regional PAin syndrome Clinical sTudies (COMPACT)

References

    1. Classification of chronic pain, Second Edition (revised) IASP Task Force on Taxonomy. . Accessed 1 Mar 2022.
    1. de Mos M, Sturkenboom MC, Huygen FJ. Current understandings on complex regional pain syndrome. Pain Pract. 2009;9(2):86–99. doi: 10.1111/j.1533-2500.2009.00262.x.
    1. Mangnus TJP, Bharwani KD, Dirckx M, Huygen FJPM. From a symptom-based to a mechanism-based Pharmacotherapeutic treatment in complex regional pain syndrome. Drugs. 2022.
    1. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55(9):1059–1077. doi: 10.1007/s40262-016-0383-6.
    1. Mangnus TJP, Bharwani KD, Stronks DL, Dirckx M, Huygen F. Ketamine therapy for chronic pain in the Netherlands: a nationwide survey. Scand J Pain. 2022;22(1):97–105. doi: 10.1515/sjpain-2021-0079.
    1. Yang Y, Maher DP, Cohen SP. Emerging concepts on the use of ketamine for chronic pain. Expert Rev Clin Pharmacol. 2020;13(2):135–146. doi: 10.1080/17512433.2020.1717947.
    1. Loix S, De Kock M, Henin P. The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg. 2011;62(1):47–58.
    1. Nan Z, Lihua Y, Peilin W, Zhongchun L. Immunoregulation and antidepressant effect of ketamine. Transl Neurosci. 2021;12(1):218–236. doi: 10.1515/tnsci-2020-0167.
    1. Szalach LP, Lisowska KA, Slupski J, Wlodarczyk A, Gorska N, Szarmach J, Jakuszkowiak-Wojten K, Galuszko-Wegielnik M, Wiglusz MS, Wilkowska A, et al. The immunomodulatory effect of ketamine in depression. Psychiatr Danub. 2019;31(Suppl 3):252–257.
    1. Zhao J, Wang Y, Wang D. The effect of ketamine infusion in the treatment of complex regional pain syndrome: a systemic review and Meta-analysis. Curr Pain Headache Rep. 2018;22(2):12. doi: 10.1007/s11916-018-0664-x.
    1. Chitneni A, Patil A, Dalal S, Ghorayeb JH, Pham YN, Grigoropoulos G. Use of Ketamine Infusions for Treatment of Complex Regional Pain Syndrome: A Systematic Review. Cureus. 2021;13(10):e18910. doi: 10.7759/cureus.18910.
    1. Perez R, Geertzen JHB, Dijkstra PU, Dirckx M, Van Eijs F, Frölke JP. Updated guidelines complex regional pain syndrome type 1. Utrecht: The Dutch Pain Society; 2014.
    1. Mangnus TJP, Dirckx M, Bharwani KD, de Vos CC, Frankema SPG, Stronks DL, Huygen F. Effect of intravenous low-dose S-ketamine on pain in patients with complex regional pain syndrome: a retrospective cohort study. Pain Pract. 2021;21(8):890–897. doi: 10.1111/papr.13056.
    1. Harden NR, Bruehl S, Perez R, Birklein F, Marinus J, Maihofner C, Lubenow T, Buvanendran A, Mackey S, Graciosa J, et al. Development of a severity score for CRPS. Pain. 2010;151(3):870–876. doi: 10.1016/j.pain.2010.09.031.
    1. Goebel A, Birklein F, Brunner F, Clark JD, Gierthmuhlen J, Harden N, Huygen F, Knudsen L, McCabe C, Lewis J, et al. The Valencia consensus-based adaptation of the IASP complex regional pain syndrome diagnostic criteria. Pain. 2021;162(9):2346–2348. doi: 10.1097/j.pain.0000000000002245.
    1. Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, Viscusi ER, Narouze S, Davis FN, Ritchie EC, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of pain medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521–546.
    1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Grieve S, Perez R, Birklein F, Brunner F, Bruehl S, Harden RN, Packham T, Gobeil F, Haigh R, Holly J, et al. Recommendations for a first Core outcome measurement set for complex regional PAin syndrome clinical sTudies (COMPACT) Pain. 2017;158(6):1083–1090. doi: 10.1097/j.pain.0000000000000866.
    1. Hudak PL, Wright JG. The characteristics of patient satisfaction measures. Spine (Phila Pa 1976) 2000;25(24):3167–3177. doi: 10.1097/00007632-200012150-00012.
    1. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20(10):1727–1736. doi: 10.1007/s11136-011-9903-x.
    1. Sigtermans MJ, van Hilten JJ, Bauer MCR, Arbous SM, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain. 2009;145(3):304–311. doi: 10.1016/j.pain.2009.06.023.
    1. Noppers IM, Niesters M, Aarts L, Bauer MCR, Drewes AM, Dahan A, Sarton EY. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain. 2011;152(9):2173–2178. doi: 10.1016/j.pain.2011.03.026.
    1. Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, Treede RD. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain. 2006;10(1):77–88. doi: 10.1016/j.ejpain.2005.02.003.
    1. Kennedy DL, Kemp HI, Ridout D, Yarnitsky D, Rice ASC. Reliability of conditioned pain modulation: a systematic review. Pain. 2016;157(11):2410–2419. doi: 10.1097/j.pain.0000000000000689.
    1. Bharwani KD, Dirckx M, Stronks DL, Dik WA, Schreurs MWJ, Huygen F. Elevated plasma levels of sIL-2R in complex regional pain syndrome: a pathogenic role for T-lymphocytes? Mediat Inflamm. 2017;2017:2764261. doi: 10.1155/2017/2764261.
    1. Bharwani KD, Dik WA, Dirckx M, Huygen F. Highlighting the role of biomarkers of inflammation in the diagnosis and Management of Complex Regional Pain Syndrome. Mol Diagn Ther. 2019;23(5):615–626. doi: 10.1007/s40291-019-00417-x.
    1. Huygen FJPM, Niehof S, Klein J, Zijlstra FJ. Computer-assisted skin videothermography is a highly sensitive quality tool in the diagnosis and monitoring of complex regional pain syndrome type I. Eur J Appl Physiol. 2004;91(5):516–524. doi: 10.1007/s00421-003-1037-6.
    1. Terwee CB, Roorda LD, de Vet HC, Dekker J, Westhovens R, van Leeuwen J, Cella D, Correia H, Arnold B, Perez B, Boers M. Dutch-Flemish translation of 17 item banks from the patient-reported outcomes measurement information system (PROMIS) Qual Life Res. 2014;23(6):1733–41. doi: 10.1007/s11136-013-0611-6.
    1. Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, Bhagwat D, Everton D, Burke LB, Cowan P, et al. Development and initial validation of an expanded and revised version of the short-form McGill pain questionnaire (SF-MPQ-2) Pain. 2009;144(1-2):35–42. doi: 10.1016/j.pain.2009.02.007.
    1. Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7(4):524. doi: 10.1037/1040-3590.7.4.524.
    1. Nicholas MK. The pain self-efficacy questionnaire: taking pain into account. Eur J Pain. 2007;11(2):153–163. doi: 10.1016/j.ejpain.2005.12.008.
    1. Buscher HCJL, Wilder-Smith OHG, van Goor H. Chronic pancreatitis patients show hyperalgesia of central origin: a pilot study. Eur J Pain. 2006;10(4):363–370. doi: 10.1016/j.ejpain.2005.06.006.
    1. van Laarhoven AIM, Kraaimaat FW, Wilder-Smith OH, van de Kerkhof PCM, Evers AWM. Heterotopic pruritic conditioning and itch – analogous to DNIC in pain? PAIN®. 2010;149(2):332–337. doi: 10.1016/j.pain.2010.02.026.
    1. Kriek N, de Vos CC, Groeneweg JG, Baart SJ, Huygen FJPM. Allodynia, Hyperalgesia, (Quantitative) Sensory Testing and Conditioned Pain Modulation in Patients With Complex Regional Pain Syndrome Before and After Spinal Cord Stimulation Therapy. Neuromodulation. 2023;26(1):78–86. doi: 10.1016/j.neurom.2022.06.009.
    1. Yarnitsky D, Bouhassira D, Drewes AM, Fillingim RB, Granot M, Hansson P, Landau R, Marchand S, Matre D, Nilsen KB. Recommendations on practice of conditioned pain modulation (CPM) testing. Eur J Pain. 2015;19(6):805–806. doi: 10.1002/ejp.605.
    1. Olesen SS, Graversen C, Bouwense SAW, van Goor H, Wilder-Smith OHG, Drewes AM. Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. PLoS One. 2013;8(3):e57963. doi: 10.1371/journal.pone.0057963.
    1. Bosma RL, Cheng JC, Rogachov A, Kim JA, Hemington KS, Osborne NR, Venkat Raghavan L, Bhatia A, Davis KD. Brain dynamics and temporal summation of pain predicts neuropathic pain relief from ketamine infusion. Anesthesiology. 2018;129(5):1015–1024. doi: 10.1097/ALN.0000000000002417.
    1. Niesters M, Aarts L, Sarton E, Dahan A. Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo-controlled cross-over proof-of-concept study. Br J Anaesth. 2013;110(6):1010–1016. doi: 10.1093/bja/aes578.
    1. Kirkpatrick AF, Saghafi A, Yang K, Qiu P, Alexander J, Bavry E, Schwartzman R. Optimizing the treatment of CRPS with ketamine. Clin J Pain. 2020;36(7):516–523. doi: 10.1097/AJP.0000000000000831.
    1. Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Tan S. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Diemen: Zorginstituut Nederland; 2016.
    1. Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg. 2017;124(2):661–674. doi: 10.1213/ANE.0000000000001787.
    1. Patil S, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis. Pain Med. 2012;13(2):263–269. doi: 10.1111/j.1526-4637.2011.01241.x.
    1. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009;147(1-3):107–115. doi: 10.1016/j.pain.2009.08.015.
    1. Sheehy KA, Muller EA, Lippold C, Nouraie M, Finkel JC, Quezado ZMN. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. BMC Pediatr. 2015;15(1):1–8. doi: 10.1186/s12887-015-0515-4.
    1. Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A. Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother. 2010;11(14):2417–2429. doi: 10.1517/14656566.2010.515978.
    1. Xu J, Herndon C, Anderson S, Getson P, Foorsov V, Harbut RE, Moskovitz P, Harden RN. Intravenous ketamine infusion for complex regional pain syndrome: survey, consensus, and a reference protocol. Pain Med. 2019;20(2):323–334. doi: 10.1093/pm/pny024.
    1. Sleigh J, Harvey M, Voss L, Denny B. Ketamine–More mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care. 2014;4(2-3):76–81. doi: 10.1016/j.tacc.2014.03.002.
    1. Kamp J, Van Velzen M, Olofsen E, Boon M, Dahan A, Niesters M. Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature. Expert Opin Drug Metab Toxicol. 2019;15(12):1033–1041. doi: 10.1080/17425255.2019.1689958.
    1. David Clark J, Tawfik VL, Tajerian M, Kingery WS. Autoinflammatory and autoimmune contributions to complex regional pain syndrome. Mol Pain. 2018;14:1744806918799127. doi: 10.1177/1744806918799127.
    1. Zhou Y, Wang C, Lan X, Li H, Chao Z, Ning Y. Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine. J Neuroinflammation. 2021;18(1):200. doi: 10.1186/s12974-021-02245-5.
    1. Nikkheslat N. Targeting inflammation in depression: ketamine as an anti-inflammatory antidepressant in psychiatric emergency. Brain Behav Immun Health. 2021;18:100383. doi: 10.1016/j.bbih.2021.100383.
    1. Birklein F, Ajit SK, Goebel A, Perez R, Sommer C. Complex regional pain syndrome - phenotypic characteristics and potential biomarkers. Nat Rev Neurol. 2018;14(5):272–284. doi: 10.1038/nrneurol.2018.20.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel